Professor M Francesca Cordeiro, is a clinician-scientist. She is Chair and Professor of Ophthalmology at Imperial College London, Honorary Consultant Ophthalmologist and Research Lead at the Western Eye Hospital, Imperial College Healthcare NHS Trust and Director of the Imperial College Ophthalmology Research Group (ICORG) Clinical Trials Research Unit (CTU). She is also Professor of Glaucoma and Retinal Neurodegeneration, at the Institute of Ophthalmology, University College London (UCL).
She qualified in medicine from St Bartholomew’s Hospital University of London and completed training in general and surgical ophthalmology at Moorfield’s Eye & St Thomas’ Hospitals in London in 2003, following her PhD at UCL in 1998.
Her research is translational - applying molecular and biological approaches to the treatment or pathogenesis of retinal neurodegenerative diseases, including glaucoma, Alzheimer’s, Parkinson's, optic neuritis and diabetes. Early clinical trials stemming from basic science research are performed in the Imperial College Ophthalmology Research Group (ICORG) Clinical Trials Unit, and the aims of this work are to establish new methods of diagnosis of early disease to avoid disability, identify early markers of cell processes in neurodegenerative disease and investigate therapeutic approaches including novel modes of drug delivery and improved treatment strategies.
Her research has been funded by the Wellcome Trust since 1996, including a Vision Research Fellowship, a University Award, a Wellcome Translational Award for the DARC Project and most recently, a Wellcome HICF Award for a Drug Delivery Project.
She serves on a number of international committees and is currently responsible for glaucoma programmes for ARVO (2017 - 2020), COphy, ISOPT, EVI and EVICRnet, the whole conference programme for EVER (2017 - 2022), and chairs the EGS Neuroprotection SIG. She is on the Editorial Board of various journals including Investigative Ophthalmology, Experimental Eye Research, and Ophthalmic Research.
et al., 2021, Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic., Prog Retin Eye Res
et al., 2017, Real-time imaging of single neuronal cell apoptosis in patients with glaucoma, Brain, Vol:140, ISSN:1460-2156, Pages:1757-1767
et al., 2017, Characterizing microglia activation: a spatial statistics approach to maximize information extraction, Scientific Reports, Vol:7, ISSN:2045-2322
et al., 2016, The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain, Acta Neuropathologica Communications, Vol:4, ISSN:2051-5960
et al., 2014, Topical delivery of Avastin to the posterior segment of the eye In vivo using annexin A5-associated liposomes, Small, Vol:10, ISSN:1613-6810, Pages:1575-1584
et al., 2014, Unexpected low-dose toxicity of the universal solvent DMSO, The FASEB Journal, Vol:28, ISSN:0892-6638, Pages:1317-1330
et al., 2010, Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo, Cell Death & Disease, Vol:1, ISSN:2041-4889
et al., 2007, Targeting amyloid-beta in glaucoma treatment, Proceedings of the National Academy of Sciences of the United States of America, Vol:104, ISSN:0027-8424, Pages:13444-13449
et al., 2005, Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix, Investigative Ophthalmology & Visual Science, Vol:46, ISSN:0146-0404, Pages:175-182
et al., 2004, Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration., Proceedings of the National Academy of Sciences of the United States of America, Vol:101, ISSN:0027-8424, Pages:13352-13356
Cordeiro MF, Gay JA, Khaw PT, 1999, Human anti-transforming growth factor-beta 2 antibody: A new glaucoma anti-scarring agent, Investigative Ophthalmology & Visual Science, Vol:40, ISSN:0146-0404, Pages:2225-2234